Aethlon Medical, Inc. (AEMD) stock forecast & analysis
6.31
NasdaqCM · USD
Down: -0.47, -6.9%
6.48Up: +0.17, +2.7%
1 analysis
- Open
- 6.40
- Previous close
- 6.78
- Day range
- 5.80 – 6.56
- 52-week range
- 1.41 – 41.50
- Volume (shares)
- 2.45M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 711.14K
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.40
- Market cap
- 4.49M
Market Scanner’s AI analysis of Aethlon Medical, Inc. (AEMD), updated September 2026: AEMD merger with North Immunology and recent price surge contrasted with long-term technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Aethlon Medical, Inc. (AEMD) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
AEMD merger with North Immunology and recent price surge contrasted with long-term technical indicators.
Recent analyses covered Aethlon Medical's (AEMD) merger with North Immunology, which aims to advance a novel bispecific antibody. The company's stock experienced a significant surge following this announcement. Market analyses noted strong short-term upward momentum and overbought technical indicators, contrasting with a bearish long-term trend.
AEMD news & sentiment
News reports highlighted a significant stock surge following the announcement of a merger aimed at advancing a novel antibody treatment. Social media discussions noted the merger as part of a broader trend in the biotech sector.
AEMD technical picture
The stock price traded significantly above its 10-day and 50-day moving averages but below its 200-day moving average. Short-term momentum readings were strong, with RSI and MFI indicating overbought conditions, while MACD suggested waning bullish momentum.
Fundamentals
The company has a negative EPS and Return on Equity, with a negative Forward PE ratio. Despite significant operating and net losses, it maintains strong short-term liquidity with a high Current Ratio and Quick Ratio.
Factors discussed — upside
- Merger with North Immunology to advance novel bispecific antibody targeting IL-13 and IL-18.
- Shares increased by over 400% following merger announcement.
- Strong short-term upward momentum indicated by 7-day and 30-day price changes.
- Strong short-term liquidity position with a Current Ratio of 5.416 and Quick Ratio of 4.762.
- Extreme buying pressure indicated by Money Flow Index (MFI) at 99.53.
Factors discussed — risks
- Stock price is below its 200-day Simple Moving Average (SMA) of 9.25, indicating a bearish long-term trend.
- Relative Strength Index (RSI) at 82.91 suggests the price may be overextended in the short term.
- MACD at -0.0185 suggests waning bullish momentum or a potential bearish crossover.
- Operating income and net income were negative for the annual report ending March 31, 2026.
- Negative Return on Equity (TTM) of -160.9%.
- Mergers and Acquisitions
- Biotech Sector Trends
- Technical Analysis
- Financial Health
Summary updated .
AEMD technical indicators
Common technical indicators for AEMD, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 2.81 | Price above |
| 10-day exponential moving average | 3.28 | Price above |
| Relative strength index (14-day) | 77.25 | Overbought |
| MACD line (12/26/9) | 0.2853 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -0.44 – 5.27 | Price above the upper band |
Analyses
Recent AEMD.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Aethlon Medical, Inc.?
- The bull case centers on the merger with North Immunology, advancing a novel bispecific antibody, which has driven a significant share price increase and strong short-term upward momentum. Analyses also noted a strong short-term liquidity position and extreme buying pressure.
- What are the risks for Aethlon Medical, Inc.?
- Risks discussed include the stock price trading below its 200-day moving average, suggesting a bearish long-term trend, and technical indicators pointing to potentially overextended short-term conditions. Furthermore, analyses highlighted negative operating and net income in the last annual report and a negative return on equity.
- Is Aethlon Medical, Inc. bullish or bearish?
- Recent AI analyses of Aethlon Medical, Inc. examined factors on both sides. Discussed upside: The bull case centers on the merger with North Immunology, advancing a novel bispecific antibody, which has driven a significant share price increase and strong short-term upward momentum. Analyses also noted a strong short-term liquidity position and extreme buying pressure. Discussed risks: Risks discussed include the stock price trading below its 200-day moving average, suggesting a bearish long-term trend, and technical indicators pointing to potentially overextended short-term conditions. Furthermore, analyses highlighted negative operating and net income in the last annual report and a negative return on equity. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Aethlon Medical, Inc.?
- News reports highlighted a significant stock surge following the announcement of a merger aimed at advancing a novel antibody treatment. Social media discussions noted the merger as part of a broader trend in the biotech sector.
- How does Market Scanner analyse Aethlon Medical, Inc.?
- Every analysis of Aethlon Medical, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh AEMD.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every AEMD.US report already in the library